| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Vlado Perkovic | Q28359591 |
| Jonathan Craig | Q38591193 | ||
| Giorgio Gentile | Q37831261 | ||
| David Johnson | Q37840488 | ||
| Mauro Cignarelli | Q114402309 | ||
| Ausilia Maione | Q114572594 | ||
| Giovanni Tognoni | Q114572595 | ||
| Valeria Maria Manfreda | Q114572597 | ||
| Salvatore De Cosmo | Q46881493 | ||
| Antonio Sasso | Q54936337 | ||
| Giusi Graziano | Q56856302 | ||
| Giovanni Strippoli | Q59680580 | ||
| Olga Lamacchia | Q92532234 | ||
| Sankar Navaneethan | Q109544900 | ||
| P2093 | author name string | Antonio Nicolucci | |
| Ruth Mitchell | |||
| Peggy Gao | |||
| Johannes F E Mann | |||
| P2860 | cites work | Measuring inconsistency in meta-analyses | Q27860655 |
| British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary | Q28167733 | ||
| Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 | ||
| The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes | Q28188182 | ||
| The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE> | Q28204197 | ||
| Prevalence of chronic kidney disease in the United States | Q29614191 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
| Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data | Q30656350 | ||
| Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. | Q31046296 | ||
| Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). | Q31437386 | ||
| Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
| Efficacy and safety of benazepril for advanced chronic renal insufficiency | Q33992851 | ||
| 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension | Q34201728 | ||
| Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi | Q34272627 | ||
| Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria | Q34504490 | ||
| Combining GFR and albuminuria to classify CKD improves prediction of ESRD. | Q34606387 | ||
| Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy | Q34754335 | ||
| Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review | Q35905849 | ||
| Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). | Q36456306 | ||
| Improving the prognosis of diabetic patients: evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor blocker (ARB) therapy | Q36697588 | ||
| Rationale for double renin-angiotensin-aldosterone system blockade | Q36897549 | ||
| Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). | Q37087865 | ||
| Lowering blood pressure reduces renal events in type 2 diabetes | Q37146445 | ||
| Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes | Q37297655 | ||
| Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity | Q39571547 | ||
| Microalbuminuria, cardiovascular risk factors and cardiovascular morbidity in a British population: the EPIC-Norfolk population-based study | Q40506095 | ||
| Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy | Q42164528 | ||
| Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells | Q42498740 | ||
| Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial | Q42542786 | ||
| Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. | Q42543650 | ||
| Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria | Q43590458 | ||
| Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. | Q43683472 | ||
| Is losartan as effective as enalapril on posttransplant persistent proteinuria? | Q43828535 | ||
| Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). | Q43857789 | ||
| Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes | Q43889672 | ||
| Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man. | Q43907231 | ||
| Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria | Q43938795 | ||
| Survival in patients with type 2 diabetes in a Swedish community: skaraborg hypertension and diabetes project | Q44081084 | ||
| The effects of losartan and fosinopril in hypertensive type 2 diabetic patients | Q44088438 | ||
| Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial | Q44280775 | ||
| Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease | Q44401497 | ||
| Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses | Q44401594 | ||
| Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects | Q44410611 | ||
| The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis | Q44588686 | ||
| Efficacy of valsartan in the therapy of persistent microalbuminuria in normotensive patients with type 1 diabetes mellitus | Q44649585 | ||
| Differing anti-proteinuric action of candesartan and losartan in chronic renal disease | Q44721681 | ||
| Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis | Q44747062 | ||
| A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy | Q44867594 | ||
| Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes | Q44947020 | ||
| Proteinuria and risk for stroke and coronary heart disease during 27 years of follow-up: the Honolulu Heart Program | Q44970745 | ||
| Microalbuminuria and stroke in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study | Q45061316 | ||
| Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. | Q45118524 | ||
| A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study | Q45150538 | ||
| Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. | Q45242324 | ||
| Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus | Q45277146 | ||
| Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study | Q45713436 | ||
| Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis. | Q46374897 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial | Q46433235 | ||
| Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis | Q46555031 | ||
| Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril | Q46601439 | ||
| Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension | Q46660460 | ||
| Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis | Q46823376 | ||
| Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study | Q46856822 | ||
| Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy | Q46874191 | ||
| The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population | Q46963308 | ||
| Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy | Q46966465 | ||
| ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects | Q47381416 | ||
| The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. | Q50593889 | ||
| Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. | Q50625243 | ||
| Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. | Q51601011 | ||
| Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. | Q53890203 | ||
| The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease | Q56867091 | ||
| Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study | Q57202781 | ||
| Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy | Q57704237 | ||
| The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency | Q58209790 | ||
| Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients | Q58209991 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systematic review | Q1504425 |
| circulatory system | Q11068 | ||
| P304 | page(s) | 2827-2847 | |
| P577 | publication date | 2011-03-03 | |
| P1433 | published in | Nephrology Dialysis Transplantation | Q15710302 |
| P1476 | title | Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials | |
| P478 | volume | 26 |
| Q91656866 | A Primer on Quality Assurance and Performance Improvement for Interprofessional Chronic Kidney Disease Care: A Path to Joint Commission Certification |
| Q34912750 | Active vitamin D treatment for reduction of residual proteinuria: a systematic review |
| Q26865691 | Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system |
| Q49136022 | Approach to cardiovascular disease prevention in patients with chronic kidney disease |
| Q34656780 | Assessment and management of resistant hypertension |
| Q33950911 | Cardiovascular risk factor treatment targets and renal complications in high risk vascular patients: a cohort study |
| Q34736194 | Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America |
| Q38502138 | Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis |
| Q38445037 | Defining, Treating, and Understanding Chronic Kidney Disease--A Complex Disorder |
| Q38654327 | Drug therapies to delay the progression of chronic kidney disease |
| Q37053287 | Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence? |
| Q49048863 | Effect of renin-angiotensin-aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis |
| Q48347744 | Effect of valsartan on kidney outcomes in people with impaired glucose tolerance |
| Q57299063 | Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials |
| Q35905899 | Emerging drug combinations to optimize renovascular protection and blood pressure goals |
| Q89727361 | Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 |
| Q39120713 | Heparanase: roles in cell survival, extracellular matrix remodelling and the development of kidney disease |
| Q39165623 | Hypertension in Chronic Kidney Disease |
| Q50074639 | Impact of achieved blood pressure on renal function decline and first stroke in hypertensive patients with chronic kidney disease |
| Q34048920 | Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals |
| Q36551388 | RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches |
| Q38137851 | Renin-angiotensin system blocking drugs. |
| Q36796579 | Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase |
| Q38806963 | Resistant Hypertension and Chronic Kidney Disease: a Dangerous Liaison |
| Q38214892 | Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases. |
| Q41552405 | The Blocking on the Cathepsin B and Fibronectin Accumulation in Kidney Glomeruli of Diabetic Rats |
| Q36967299 | The arrestin-selective angiotensin AT1 receptor agonist [Sar1,Ile4,Ile8]-AngII negatively regulates bradykinin B2 receptor signaling via AT1-B2 receptor heterodimers |
| Q51771875 | The effects of single and combined application of ramipril and losartan on renal structure and function in hypertensive rats. |
| Q58977867 | The impact of renin–angiotensin–aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy |
| Q41696181 | Time-varying maximal proteinuria correlates with adverse cardiovascular events and graft failure in kidney transplant recipients |
| Q36630037 | Wnt/β-catenin signaling and renin-angiotensin system in chronic kidney disease |
Search more.